APREA THERAPEUTICS, INC. (APRE): Price and Financial Metrics


APREA THERAPEUTICS, INC. (APRE): $0.82

0.02 (+1.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add APRE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

APRE Stock Price Chart Interactive Chart >

Price chart for APRE

APRE Price/Volume Stats

Current price $0.82 52-week high $7.80
Prev. close $0.81 52-week low $0.62
Day low $0.73 Volume 975,000
Day high $0.89 Avg. volume 435,527
50-day MA $1.43 Dividend yield N/A
200-day MA $3.06 Market Cap 18.02M

APREA THERAPEUTICS, INC. (APRE) Company Bio


Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.


APRE Latest News Stream


Event/Time News Detail
Loading, please wait...

APRE Latest Social Stream


Loading social stream, please wait...

View Full APRE Social Stream

Latest APRE News From Around the Web

Below are the latest news stories about Aprea Therapeutics Inc that investors may wish to consider to help them evaluate APRE as an investment opportunity.

Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | January 14, 2022

Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 11:15 a.m. ET. A live webcast of the presentation can be accessed

Yahoo | January 6, 2022

Aprea Therapeutics (NASDAQ:APRE) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Aprea Therapeutics (NASDAQ:APRE) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, []

Dakota Financial News | December 20, 2021

Aprea Therapeutics (NASDAQ:APRE) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a hold rating to a buy rating in a research note issued to investors on Friday morning, Zacks.com reports. The brokerage currently has $3.75 target price on the stock. According to Zacks, Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and []

Dakota Financial News | December 20, 2021

Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting

BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of Aprea Therapeutics, Inc. (Nasdaq: APRE) lead product candidate, eprenetapopt .

Intrado Digital Media | December 14, 2021

Read More 'APRE' Stories Here

APRE Price Returns

1-mo -44.97%
3-mo -52.87%
6-mo -80.24%
1-year -80.24%
3-year N/A
5-year N/A
YTD -71.43%
2021 -41.67%
2020 -89.28%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7796 seconds.